ASH SAP

Question 1

Preferred first line for primary CNS lymphoma

Answer 1

MATrix (Preferred – MTX + thiotepa + rituxan

Question 2

Virus associated with PTLD

Answer 2

EBV

Question 3

IHC specific finding of activated b cell subtype

Answer 3

MUM1

Question 4

First line for anaplastic large t cell lymphoma

Answer 4

Brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone (A-CHP) (ECHELON-2)

Question 5

ALCL stands for

Answer 5

anaplastic large cell lymphoma

Question 6

Favorable prognostic marker in ALCL

Answer 6

DUSP22 rearrangement

Question 7

First line therapy for ALCL + components

Answer 7

Brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone (A-CHP) (ECHELON-2)

Question 8

ALCL consolidation

Answer 8

Transplant

Question 9

Clinical presentation of angioimmunoblastic lymphoma

Answer 9

hemolytic anemia

Question 10

AITL phenotype

Answer 10

CD4+, CD8-, expanded CD21+ follicular dendritic cell network, CD10, and PDL1+

Question 11

Initial management of MCL

Answer 11

• depends on whether indolent disease or aggressive
• IF indolent, observation if no indications for treatment
• IF aggressive, BR preferred at UMASS (CONFIRM)

Question 12

Bexarotene for CTCL AE’s

Answer 12

• hypertriglyceridemia
• central hypothyroidism

Question 13

characteristic gene mutation in hairy cell

Answer 13

BRAF V600E

Question 14

Translocation associated with reduced responsiveness to h pylori treatment in MALT lymphoma

Answer 14

t(11;18)

Question 15

Marginal zone lymphoma immunophenotype

Answer 15

CD10-

Question 16

What degree of tumor burden indicates treatment in FL

Answer 16

High tumor burden defined as:
Tumor >7 cm
3 nodes in 3 distinct areas, each > 3 cm in diameter
Symptomatic splenomegaly
Ascites or pleural effusion

Question 17

t(14;18) chromosomal translocation in FL pairs BCL2 with which gene?

Answer 17

IGH

Question 18

Translocation associated with favorable response in anaplastic large cell lymphoma

Answer 18

t(2;5)

Question 19

Clinical features of primary effusion lymphoma (PEL)

Answer 19

1) neoplastic effusion
2),typically in setting of immunosuppression (post transplant or HIV)
3) no significant adenopathy or tumor masses

Question 20

Viruses associated with PEL

Answer 20

HHV8 (kaposi sarcoma-associated herpesvirus)

Question 21

Gene mutation associated with ALCL

Answer 21

ALK, the Anaplastic Lymphoma Kinase gene

Question 22

Gene associated with primary cutaneous ALCL

Answer 22

MUM1/IRF4 gene.